New hope for deadliest breast cancer complication: drug combo trial launches

NCT ID NCT06462092

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs—sacituzumab govitecan (given through a vein) and pemetrexed (given into the spinal fluid)—for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). This condition is very serious, with survival typically only 3-6 months. The trial aims to find a safe dose and see if the combo can help control the disease. About 34 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Meningeal Carcinomatosis neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Affiliated Huizhou Hospital, Guangzhou Medical University

    RECRUITING

    Huizhou, Guangdong, 516000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact